Back
HuagongsheHuagongshe Chemistry Print Report · For research reference only
HRID 534900Generated: October 25, 2026

Potassium Carbonate → tert-Butyl [(5-{[4-(2-tert-butylphenyl)piperazin-1-yl]carbonyl}pyridin-3-yl)oxy]acetate

https://huagongshe.com/reaction/534900

Reaction equation

Participants

RoleNameHCIDCharge
ReactantPotassium CarbonateHCID 11430—
Reactant5-Hydroxynicotinic acidHCID 34037—
Reactanttert-Butyl bromoacetateHCID 79177—
Reactant1,3-Propanediamine, N'-(ethylcarbonimidoyl)-N,N-dimethyl-, monohydrochlorideHCID 2723939—
Reactant1-Hydroxybenzotriazole hydrateHCID 2796029—
Reactant1-(2-Tert-butylphenyl)piperazine dihydrochlorideHCID 66751149—
SolventWaterHCID 962—
SolventDimethylformamideHCID 6228—
SolventTriethylamineHCID 8471—
Producttert-Butyl [(5-{[4-(2-tert-butylphenyl)piperazin-1-yl]carbonyl}pyridin-3-yl)oxy]acetateHCID 6675133368%

Reaction Steps

A mixture of 1-(2-tert-butylphenyl)piperazine dihydrochloride obtained in Reference Example 1 (500 mg), 5-hydroxypyridine-3-carboxylic acid (287 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (403 mg), 1-hydroxy-1H-benzotriazole monohydrate (322 mg), triethylamine (0.488 mL), and N,N-dimethylformamide (5 mL) was stirred at room temperature for 16 h. Water was added to the reaction solution, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure to provide a powder (LC/MS (ESI+) m/z: 340 (M+H)+). A mixture of the powder, tert-butyl bromoacetate (683 mg), potassium carbonate (691 mg), and N,N-dimethylformamide (10 mL) was stirred at 60° C. for 5 h. Water was added to the reaction solution, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by flash column chromatography (silica gel, 90:10-50:50 hexane/ethyl acetate) to provide the title compound (530 mg, 68%) as crystals.

Provenance & Evidence

DOI10.6084/m9.figshare.5104873.v1
Patent numberUS08853215B2
Source datasetuspto-grants-2014_10
ORD IDord-1592e319a7094da195ccc565a1fcb5eb
Source noteuspto-grants-2014_10